Please find information below about the 2019 ASCO Annual Meeting, which will take place Friday, May 31 - Tuesday, June 4, 2019, at McCormick Place in Chicago, IL. If you are a public relations professional looking for meeting information, please see our For PR Professionals page.

Key Dates

  • Media registration opens: Monday, March 4
  • Hotel reservation deadline: Wednesday, April 24
  • Embargoed presscast for credentialed media: Wednesday, May 15
  • Final deadline for pre-registration: Friday, May 17
  • 2019 ASCO Annual Meeting: Friday, May 31 - Tuesday, June 4

Register to Attend the Meeting in Person/Access Embargoed Materials

Media registration for the 2019 ASCO Annual Meeting will open on March 4, 2019. At that time, you can visit ASCO's Media Headquarters to apply for media credentials, register to attend the meeting, access embargoed meeting information, and locate presscast dial-in information. For questions about how to navigate the site, please contact ASCO Media Registration.

Meeting Information

Past Meetings: 2018 ASCO Annual Meeting

Press Program Announcement:

  • New, High-Impact Studies to Be Featured at World’s Largest Clinical Cancer Research Meeting
    ALEXANDRIA, Va. – The latest in clinical cancer research, from new treatment options and advances in precision medicine to insights for improving access to care, will be highlighted in the official Press Program for the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO). Read the full release.

May 16 Presscast:

  • Shorter Trastuzumab Treatment for HER2+ Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects
    ALEXANDRIA, Va. – A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. Read the full release.
     
  • Use of Mobile and Sensor Technology Lowers Symptom Severity for People With Head and Neck Cancer
    ALEXANDRIA, Va. – A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related). Read the full release.
     
  • Vast Majority of Heavy Smokers Not Screened for Lung Cancer Despite USPSTF Recommendations
    ALEXANDRIA, Va. – An analysis of 1,800 lung cancer screening sites nationwide found that only 1.9% of more than 7 million current and former heavy smokers were screened for lung cancer in 2016, despite United States Preventive Services Task Force (USPSTF) and ASCO screening recommendations. Read the full release.
     
  • Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Effective
    ALEXANDRIA, Va. – An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more cost-effective and faster than testing one or a limited number of genes at a time. Read the full release.
     
  • More Choices for Treating Insomnia in Cancer Survivors: Acupuncture and Cognitive Behavioral Therapy
    ALEXANDRIA, Va. – A Patient-Centered Outcomes Research Institute (PCORI)-supported randomized clinical trial of cancer survivors showed that eight weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among patients receiving cognitive behavioral therapy. Read the full release.
     
  • New Regimens Improve Survival for Children and Young Adults With T-Cell Cancers
    ALEXANDRIA, Va. – In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive 4 years after starting treatment regimens on this trial, and 84% were cancer-free. Read the full release.

Friday, June 1 Press Briefing: 

  • Treatment for Colorectal Cancer in Washington State Costs Twice as Much as in Neighboring Area of Canada, Despite No Difference in Survival
    CHICAGO – An analysis of health claims data from two demographically similar regions on either side of the U.S. and Canada border shows that a common treatment for advanced colorectal cancer costs twice as much in Western Washington State (WW) than in British Columbia (BC) -- $12,345 vs. $6,195 monthly per patient. Read the full release.
     
  • Black Men With Advanced Prostate Cancer Treated With Chemotherapy May Have Equal or Better Survival Than White Men
    CHICAGO – An analysis of pooled data from nine randomized phase III trials of more than 8,000 men with advanced prostate cancer who received chemotherapy shows chances of survival are as good for black men as white men. Read the full release.
     
  • Abiraterone May Be More Effective in Black Men With Advanced Prostate Cancer Than in White Men
    CHICAGO – In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Zytiga®) was greater and longer lasting in black men than in white men. Read the full release.
     
  • Study Finds Gender Disparities in Head and Neck Cancer Treatment and Outcomes
    CHICAGO – An analysis of cancer registry data from a California hospital system shows that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs. 46%) and radiation (60% vs. 70%) compared to men. Read the full release.
     
  • Geriatric Assessment Improves Communication Between Oncologists and Older Patients
    CHICAGO – A federally funded randomized study demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication. Read the full release.

Saturday, June 2 Press Briefing:

  • New Targeted Therapy Slows Growth of Advanced Breast Cancer
    CHICAGO – In a phase III clinical trial, a new targeted medicine, taselisib, combined with standard hormone therapy fulvestrant (Faslodex®), halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%. Read the full release.
     
  • Genomic Study Finds Lynch Syndrome Is Common Among People With MSI-High Tumors
    CHICAGO – A genomic study of more than 15,000 tumor samples shows that people with tumors that have high microsatellite instability (MSI-H) – a genomic marker associated with a large number of genetic mutations in the tumor – are more likely to have Lynch syndrome, a hereditary condition that increases a person’s risk of developing many different types of cancer. Read the full release.
     
  • Matching Treatment to Genetic Changes in the Tumor Improves Survival Across Multiple Cancer Types
    CHICAGO – Researchers conducted a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large, personalized medicine trial. They found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types. Read the full release.
     
  • Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer
    CHICAGO – An initial report from the large, ongoing Circulating Cell-Free Genome Atlas (CCGA) study provides preliminary evidence that a blood test may be able to detect early-stage lung cancer. Read the full release.
     
  • Adding Atezolizumab Immunotherapy to Chemotherapy Slows Growth of Advanced Squamous Lung Cancer
    CHICAGO – Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq®) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone. Read the full release.

Sunday, June 3 Press Briefing:

  • Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test
    CHICAGO – A federally funded phase III clinical trial shows that most women with hormone receptor-positive, HER2-negative, axillary node-negative early-stage breast cancer and a mid-range score on a 21-tumor gene expression assay (Oncotype DX® Breast Recurrence Score) do not need chemotherapy after surgery. Read the full release.
     
  • Maintenance Chemotherapy Extends Life for Children With a Rare Cancer – First Treatment Advance for This Cancer in 30 Years
    CHICAGO – A new chemotherapy strategy improves cure rates for children with rhabdomyosarcoma (a rare cancer of the muscle tissue) who are at high risk for cancer recurrence. Read the full release.
     
  • Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery
    CHICAGO – A randomized phase III clinical trial showed that many people with advanced kidney cancer can avoid surgery to remove the kidney (nephrectomy), without compromising survival. Read the full release.
     
  • Immunotherapy Pembrolizumab Works Better Than Chemotherapy Alone as Initial Treatment for Most Advanced Lung Cancers
    CHICAGO – A large, randomized phase III trial shows that the immunotherapy pembrolizumab (Keytruda®) is a more effective initial treatment than chemotherapy (the current standard of care) for the majority of patients with the most common type of lung cancer. Read the full release.

Monday, June 4 Press Briefing:

  • Heated Abdominal Chemotherapy Not Beneficial in Patients With Advanced Colorectal Cancer
    CHICAGO – A randomized phase III clinical trial shows that people with advanced colorectal cancer may not need a frequently considered component of treatment: heated chemotherapy delivered to the abdomen during surgery. Read the full release.
     
  • Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer
    CHICAGO – In a randomized phase III trial people with surgically removed pancreatic cancer who received mFOLFIRINOX, a chemotherapy regimen containing four different medicines, lived a median of 20 months longer and were cancer-free nine months longer than those who received the current standard of care, gemcitabine (Gemzar®). Read the full release.
     
  • Pre-Operative Chemotherapy With Radiation May Help People With Pancreatic Cancer Live Longer
    CHICAGO – A randomized, phase III trial found that people who received chemotherapy with radiation (chemoradiotherapy) before pancreatic cancer surgery had better disease-free survival than those who started their treatment with surgery, which is the current standard of care. Read the full release.
     
  • Taking Acid-Reducing Medicine With Aspirin Offers Moderate Benefits in Patients With Barrett’s Esophagus
    CHICAGO – Findings from an updated analysis from a randomized phase III trial show that taking a high dose of the acid-reducing medicine esomeprazole (Nexium®) with low dose aspirin for at least 7 years can moderately reduce the risk of developing high grade dysplasia (a pre-cancerous lesion) or esophageal cancer, or delay death from any cause in people with Barrett’s esophagus. Read the full release.

Press Briefing Recordings:

Media Resources

How Can We Help You?